Literature DB >> 23075333

Inflammation and the pathogenesis of diabetic nephropathy.

Jun Wada1, Hirofumi Makino.   

Abstract

The most problematic issue in clinical nephrology is the relentless and progressive increase in patients with ESRD (end-stage renal disease) worldwide. The impact of diabetic nephropathy on the increasing population with CKD (chronic kidney disease) and ESRD is enormous. Three major pathways showing abnormality of intracellular metabolism have been identified in the development of diabetic nephropathy: (i) the activation of polyol and PKC (protein kinase C) pathways; (ii) the formation of advanced glycation end-products; and (iii) intraglomerular hypertension induced by glomerular hyperfiltration. Upstream of these three major pathways, hyperglycaemia is the major driving force of the progression to ESRD from diabetic nephropathy. Downstream of the three pathways, microinflammation and subsequent extracellular matrix expansion are common pathways for the progression of diabetic nephropathy. In recent years, many researchers have been convinced that the inflammation pathways play central roles in the progression of diabetic nephropathy, and the identification of new inflammatory molecules may link to the development of new therapeutic strategies. Various molecules related to the inflammation pathways in diabetic nephropathy include transcription factors, pro-inflammatory cytokines, chemokines, adhesion molecules, Toll-like receptors, adipokines and nuclear receptors, which are candidates for the new molecular targets for the treatment of diabetic nephropathy. Understanding of these molecular pathways of inflammation would translate into the development of anti-inflammation therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23075333     DOI: 10.1042/CS20120198

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  220 in total

1.  Histone demethylase UTX is a therapeutic target for diabetic kidney disease.

Authors:  Hong Chen; Yixue Huang; Xiuqin Zhu; Chong Liu; Yangmian Yuan; Hua Su; Chun Zhang; Chengyu Liu; Mingrui Xiong; Yannan Qu; Peng Yun; Ling Zheng; Kun Huang
Journal:  J Physiol       Date:  2018-12-25       Impact factor: 5.182

2.  Role of adenylyl cyclase activator in controlling experimental diabetic nephropathy in rats.

Authors:  Lakhwinder Singh; Surbhi Rana; Sidharth Mehan
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2018-10-29

Review 3.  Uremic Toxicity of Advanced Glycation End Products in CKD.

Authors:  Andréa E M Stinghen; Ziad A Massy; Helen Vlassara; Gary E Striker; Agnès Boullier
Journal:  J Am Soc Nephrol       Date:  2015-08-26       Impact factor: 10.121

4.  Serum carbohydrate antigen 153 and renal function in patients with type 2 diabetes mellitus.

Authors:  You-Fan Peng; Hao Lin; Man-Man Han; Ling Li
Journal:  J Clin Lab Anal       Date:  2018-04-27       Impact factor: 2.352

Review 5.  Adipokines protecting CKD.

Authors:  Satoshi Miyamoto; Kumar Sharma
Journal:  Nephrol Dial Transplant       Date:  2013-11       Impact factor: 5.992

6.  Efficacy of aliskiren, compared with angiotensin II blockade, in slowing the progression of diabetic nephropathy in db/db mice: should the combination therapy be a focus?

Authors:  Guangyu Zhou; Xia Liu; Alfred K Cheung; Yufeng Huang
Journal:  Am J Transl Res       Date:  2015-05-15       Impact factor: 4.060

Review 7.  Glycemic memories and the epigenetic component of diabetic nephropathy.

Authors:  Samuel T Keating; Assam El-Osta
Journal:  Curr Diab Rep       Date:  2013-08       Impact factor: 4.810

8.  MicroRNA-155 Mediates Obesity-Induced Renal Inflammation and Dysfunction.

Authors:  Chenfei Zheng; Ji Zhang; Xinxin Chen; Jianna Zhang; Xiaokai Ding; Xiaohan You; Lin Fan; Chaosheng Chen; Ying Zhou
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

Review 9.  Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives.

Authors:  Ankur Jindal; Mariana Garcia-Touza; Nidhi Jindal; Adam Whaley-Connell; James R Sowers
Journal:  Endocrinol Metab Clin North Am       Date:  2013-08-01       Impact factor: 4.741

Review 10.  Remnant nephron physiology and the progression of chronic kidney disease.

Authors:  H William Schnaper
Journal:  Pediatr Nephrol       Date:  2013-05-29       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.